Athena Bioscience v. Novitium Pharma: Tramadol Patent Dispute Ends in Mutual Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Athena Bioscience, LLC v. Novitium Pharma, LLC |
| Case Number | 1:24-cv-01421 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2024 – Sep 2025 255 days |
| Outcome | Stipulated Dismissal – No Ruling on Merits |
| Patents at Issue | |
| Accused Products | Novitium Pharma’s Tramadol Hydrochloride Oral Solution 5 mg/mL |
Case Overview
The Parties
⚖️ Plaintiff
Plaintiff asserting ownership of pharmaceutical patents covering tramadol hydrochloride oral solution formulations and branded product QDOLO®.
🛡️ Defendant
New Jersey-based generic pharmaceutical manufacturer developing and commercializing complex generics, including oral solutions.
Patents at Issue
This case involved two U.S. patents protecting QDOLO® (tramadol hydrochloride oral solution, 5 mg/mL), an analgesic formulation used in pain management:
- • US 11,103,452 B2 — covering formulation or method-of-use claims related to tramadol hydrochloride oral solution
- • US 11,752,103 B2 — a related patent in the same family, likely covering additional claim scope over the same or related formulations
Developing a generic drug product?
Check if your pharmaceutical formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case was resolved through a stipulated voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), where both parties agreed to dismiss all claims and bear their own costs. No judicial ruling on infringement or patent validity was issued.
Legal Significance
The absence of a merited judgment means the patents-in-suit (U.S. Patent Nos. 11,103,452 and 11,752,103) remain valid and enforceable, preserving the patent holder’s position without an adverse court finding.
Drafting a pharmaceutical patent?
Learn from this case’s strategy. Use AI to draft stronger formulation claims.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related pharmaceutical patents in this therapeutic space
- See which companies are most active in drug formulation patents
- Understand litigation strategies in ANDA disputes
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your generic drug formulation or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for your ANDA
High Risk Area
Tramadol hydrochloride oral solution formulations
2 Patents Remain Active
Protecting QDOLO® formulation
Strategic Dismissal
Preserves patent validity for Athena Bioscience
✅ Key Takeaways
For Patent Attorneys & Litigators
A Rule 41(a)(1)(A)(ii) stipulated dismissal preserves patent validity with no adverse merit finding — a strategically valuable outcome for patent holders.
Search related case law →Delaware District Court remains the preeminent forum for pharmaceutical patent infringement actions.
Explore precedents →For IP Professionals & R&D Teams
U.S. Patent Nos. 11,103,452 and 11,752,103 remain active and enforceable — monitor for future ANDA-related assertion activity.
Start FTO analysis for my product →Conduct updated FTO analysis against the QDOLO® patent family before advancing generic tramadol oral solution development.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.